Aerie Pharmaceuticals Inc Operating margin
What is the Operating margin of Aerie Pharmaceuticals Inc?
The Operating margin of Aerie Pharmaceuticals Inc is -12.49%
What is the definition of Operating margin?
Operating margin is the ratio of operating income divided by net sales and presented in percent.
ttm (trailing twelve months)
Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.
Operating margin of companies in the Health Care sector on NASDAQ compared to Aerie Pharmaceuticals Inc
What does Aerie Pharmaceuticals Inc do?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Companies with operating margin similar to Aerie Pharmaceuticals Inc
- Reliance Industrial Infrastructure has Operating margin of -12.51%
- Fresh Express Delivery Co has Operating margin of -12.51%
- Manfield Chemical has Operating margin of -12.50%
- Northeast Electric Development has Operating margin of -12.50%
- BlackBerry has Operating margin of -12.50%
- Little Green Pharma Ltd has Operating margin of -12.49%
- Aerie Pharmaceuticals Inc has Operating margin of -12.49%
- Tasty plc has Operating margin of -12.48%
- Uniphos Enterprises has Operating margin of -12.48%
- Perma-Fix Environmental Services has Operating margin of -12.48%
- Misonix Inc has Operating margin of -12.48%
- RIWI has Operating margin of -12.46%
- Altareit SCA has Operating margin of -12.45%